Ge Long Hui A P P·2025-11-19 06:27Core Viewpoint - The report from Huazhong Securities indicates that Te Yi Pharmaceutical's net profit attributable to shareholders for the first three quarters of 2025 reached 0.65 billion yuan, representing a year-on-year increase of 985.18% [1] Financial Performance - The company has shown a rapid recovery in performance, with significant improvements in profitability due to marketing reforms [1] - The sales volume of the core product, cough tablets, for the first three quarters of 2025 was 4.35 billion pieces, which is 64% of the sales volume in the same period of 2023, exceeding initial expectations [1] Marketing Strategy - The company is focusing on cough tablets as a major product for marketing promotion and brand building [1] - Following the completion of the marketing system reform, the company aims to achieve an annual sales target of 100 million boxes of cough tablets within approximately 3-5 years, while also increasing pharmacy channel coverage to around 40% [1] Investment Rating - The investment rating is maintained at "Buy" [1]